ACHV
Achieve Life Sciences, Inc.·Healthcare
3.49
5.120%(+0.17)
Market ClosedLast Updated: — ET
52W L: $1.9552W H: $6.03
ACHV NEWS
seekingalpha.com
Apr 1
Achieve Life Sciences: The Recent Sell Off Skews The Outcomes
Achieve Life Sciences is rated Buy for risk-tolerant investors after a sharp sell-off tied to FDA manufacturing concerns. Cytisinicline demonstrates strong efficacy and a superior safety profile versus Chantix, supporting blockbuster potential in smoking cessation. Manufacturing issues prompted a supplier switch to Adare Pharma; FDA approval probability is estimated at 35% on the first try, rising to 70% if resubmitted.
seekingalpha.com
Mar 26
Achieve Life Sciences: Maintaining 'Buy' On Upcoming PDUFA And Expansion Into Vaping Cessation
Achieve Life Sciences remains a 'Buy' as cytisinicline's NDA for smoking cessation is under FDA review with a PDUFA date of June 20, 2026. ACHV exceeded long-term safety study requirements and secured a manufacturing partnership, positioning for a potential 1H 2027 commercial launch if approved. The company plans to initiate the phase 3 ORCA-V2 trial for vaping cessation in 1H 2026, targeting a large, underserved market segment.
globenewswire.com
Mar 26
Achieve Life Sciences Announces Publication in Nicotine & Tobacco Research Linking Cytisinicline's Receptor Selectivity to Low Nausea Rates and Favorable Tolerability
SEATTLE and VANCOUVER, British Columbia, March 26, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced the publication of a manuscript in Nicotine & Tobacco Research describing the receptor selectivity profile of cytisinicline. This study provides mechanistic characterization of cytisinicline's receptor selectivity profile, which informs understanding of its favorable tolerability.
seekingalpha.com
Mar 24
Achieve Life Sciences, Inc. (ACHV) Q4 2025 Earnings Call Transcript
Achieve Life Sciences, Inc. (ACHV) Q4 2025 Earnings Call Transcript
newsfilecorp.com
Mar 24
Achieve Life Sciences Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
San Diego, California--(Newsfile Corp. - March 24, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Achieve Life Sciences, Inc. (NASDAQ: ACHV). The investigation focuses on Achieve Life Sciences executive officers and whether investor losses may be recovered under federal securities laws.
globenewswire.com
Mar 24
Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Achieve also Announces Partnership with U.S.-based Adare Pharma Solutions for Cytisinicline Manufacturing Conference Call Scheduled for 8:30 AM EDT Today, March 24, 2026 SEATTLE and VANCOUVER, British Columbia, March 24, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced financial results for the fourth quarter and full year 2025 and provided updates on the cytisinicline development program, including the announcement of its partnership with Adare Pharma Solutions (Adare). “Achieve is fully committed to bringing cytisinicline to the millions of people who continue to struggle with nicotine dependence and need a new solution to help them quit.
